The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bayer
 
Employment - Bayer
Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Catherine T Frenette
Honoraria - Wako Diagnostics
Consulting or Advisory Role - Bayer; Conatus; Eisai; Exelixis; Gilead Sciences
Speakers' Bureau - Abbvie; Bayer; Bristol-Myers Squibb; Dova Pharmaceuticals; Eisai; Exelixis; Gilead Sciences; Intercept Pharmaceuticals; Salix; Shionogi
Research Funding - Bayer (Inst); Conatus (Inst); GENFIT (Inst)
 
Gianluca Masi
No Relationships to Disclose
 
Yoon Jun Kim
Honoraria - Abbvie
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - BTG; Merck Sharp & Dohme
Expert Testimony - PharmaKing
 
René Gerolami
Consulting or Advisory Role - Bayer; Eisai; Ipsen
Travel, Accommodations, Expenses - Bayer
 
Masayuki Kurosaki
Consulting or Advisory Role - Bayer; Eisai
Speakers' Bureau - Bayer; Eisai
 
Kazushi Numata
No Relationships to Disclose
 
Heinz-Josef Klümpen
Consulting or Advisory Role - Ipsen
Research Funding - Bayer (Inst); Exelixis (Inst); Ipsen (Inst); Sirtex Medical (Inst); Taiho Pharmaceutical (Inst)
 
Hong Zebger-Gong
No Relationships to Disclose
 
Sabine Fiala-Buskies
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Kirhan Ozgurdal
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose